- Government is responsible for procurement of severe malaria (SM) treatments
- National essential drug kits for health posts and health centres include RAS – supply based on consumption
- Injectable AS is individually delivered
- Hospitals are in charge of self-procurement
- No funding requested for SM drugs in last Global Fund concept note
For the first half of 2016, many Angolan hospitals reported an increase in confirmed malaria cases and deaths. Many of these reports have originated from the capital city of Luanda, but other Angolan municipalities in other provinces have experienced an increase as well. One possible factor: overall lack of malaria commodities, due to the inability to purchase necessary amounts of RDTs and ACTs.
A 2016 health facility survey in 44 health facilities in 2 provinces conducted by PMI showed:
- Shortages of severe malaria drugs in two provinces
- Critical need for increasing the number of supportive supervisory visits to improve the quality of case management
IV quinine is the third-line option for treatment of severe malaria, but is commonly used due to unavailability of IV artesunate or IM artemether.
- GRA plans to use IM artemether preferentially in peripheral health facilities, reserving IV artesunate for larger hospitals with the capacity to provide IV treatment
- President’s Malaria Initiative (PMI) plans to procure approximately one quarter of the need for severe malaria treatments to complement GRA procurement
- No rectal artesunate suppositories (RAS) will be procured with PMI funding due to the low numbers of available community health workers and the current lack of training in this intervention modality.